Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices | May 22

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Health Chair Brett Guthrie (R-KY) announced a hearing titled "Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices."

“America remains the leader in developing cutting edge biomedical innovation. Countries around the globe look to the FDA for guidance on facilitating safe and effective treatments and medical devices,” said Chairs Rodgers and Guthrie.

“Given the increased funding provided in the most recent user fee reauthorization, it’s important that we engage regularly with key FDA officials to better understand what’s working well at the FDA and what challenges persist. Continuing to rebuild public trust in government health agencies is critical and will require more transparency from agencies like the FDA.”

Subcommittee on Health hearing titled "Check Up: Examining FDA Regulation of Drugs, Biologics, and Devices."

WITNESSES:
- Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research (CDER), Food and Drug Administration
- Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration
- Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health (CDRH), Food and Drug Administration